Sirtris Pharmaceuticals Announces the Appointment of Jeffrey Capello, SVP and CFO of PerkinElmer, to its Board of Directors
January 02 2008 - 3:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that Mr. Jeffrey Capello, Senior Vice President and Chief Financial
Officer of PerkinElmer, Inc. has been appointed to its Board of
Directors. Prior to joining PerkinElmer in 2001, Mr. Capello served
as a partner at PricewaterhouseCoopers initially in the United
States and later in the Netherlands. Mr. Capello, a licensed CPA,
holds a Bachelor of Science degree in Business Administration from
the University of Vermont and a Masters of Business Administration
degree from Harvard University. �Sirtris is very pleased to welcome
Mr. Capello to our Board of Directors. Jeff brings with him
extensive experience in the finance and business development areas
and will be a tremendous asset to our organization,� said Christoph
Westphal, M.D., Ph.D. CEO and Vice Chair of Sirtris
Pharmaceuticals, Inc. Mr. Capello commented, �I am very pleased to
be joining the Board of such a dynamic and exciting
biopharmaceutical company. Sirtris has done an impressive job
advancing both the science and clinical development of
sirtuin-focused drug candidates to treat diseases of aging, and I
look forward to being a part of the company�s efforts moving
forward.� This appointment follows the resignations of Alan Crane
and John Freund. Christoph Westphal stated, �I would like to take
this opportunity to thank Alan and John for their significant
contributions to the Sirtris Board and for their support of the
company over the past three years.� About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators for diseases of aging, such as Type 2 Diabetes
and disorders, such as MELAS, the progress and results of
pre-clinical studies of SIRT1 activators, and the potential of
sirtuin modulators to receive regulatory approval. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company�s product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of
the�Company to gain market acceptance of the Company's product
candidates, and those other risks factors�that can be found in
the�Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles